title: Positively charged synthetic peptides from structural proteins of papillomaviruses abrogate human papillomavirus infectivity.
abstract: Human papillomavirus (HPV) virus-like particles (VLP) and synthetic peptides corresponding to positively-charged sequences of the major and minor capsid proteins were tested for their efficacy in inhibiting the infectivity of HPV 31 pseudovirions by blocking virus entry into cells. A greater than 80% reduction of transfection was observed with one HPV-31 peptide at a concentration of 10 microg/ml. Moreover, the blocking was not type-specific since similar reduction in transfection was observed with peptides from other HPV types at a concentration of 60 microg/ml. This concentration was non-toxic for the cells. These findings indicate that some of the positively-charged sequences of the L1 and L2 HPV capsid proteins of papillomavirus are compounds that might be locally active against sexually transmitted papillomavirus. The findings provide further evidence that cellular glycosamino-glycans (GAGs) are functional receptors for HPVs.
authors.affiliation: Laboratoire de Virologie Moléculaire, INSERM U618, Faculté de Pharmacie, Tours, France.
authors.forename: Latifa
authors.initials: L
authors.lastname: Bousarghin
authors.forename: Antoine
authors.initials: A
authors.lastname: Touzé
authors.forename: Bernard
authors.initials: B
authors.lastname: Yvonnet
authors.forename: Pierre
authors.initials: P
authors.lastname: Coursaget
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000138:chemical synthesis / Q000302:isolation & purification / Q000494:pharmacology*; D019556:COS Cells; D036022:Capsid Proteins / Q000737:chemistry / Q000235:genetics / Q000302:isolation & purification / Q000494:pharmacology*; D002460:Cell Line; D002522:Chlorocebus aethiops; D006025:Glycosaminoglycans / Q000037:antagonists & inhibitors / Q000502:physiology; D009842:Oligopeptides / Q000138:chemical synthesis / Q000494:pharmacology*; D009856:Oncogene Proteins, Viral / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology; D027383:Papillomaviridae / Q000737:chemistry* / Q000187:drug effects*; D030361:Papillomavirus Infections / Q000517:prevention & control; D011991:Receptors, Virus / Q000037:antagonists & inhibitors
chemical_list: D000998:Antiviral Agents; D036022:Capsid Proteins; D006025:Glycosaminoglycans; C114580:HPV L1 protein, Human papillomavirus; D009842:Oligopeptides; D009856:Oncogene Proteins, Viral; D011991:Receptors, Virus